The clinical features and treatment responses of immunoglobulin A (IgA)-mediated epidermolysis bullosa acquisita(IgA-mediated EBA) and linear IgA bullous dermatosis (LABD) are characterized.
A novel study asks: Does a correlation exist between preexisting comorbidities and serum titers of anti-BP180 and 230 antibodies in patients with bullous pemphigoid (BP)?
Researchers evaluated the prevalence and severity of dermatologic inflammatory conditions in patients with IBD.
The prevalence of psoriasis in patients with bullous pemphigoid (BP) was estimated and the clinical and immunological features of patients with BP and psoriasis was clarified.
Researchers sought to calculate BPDAI cut-off values defining mild, moderate, and severe bullous pemphigoid.
The burden of pruritus in patients with chronic dermatoses was characterized in this investigation.
The burden of bullous pemphigoid in the elderly population includes considerable risk for mortality; it should not be viewed as a rare disease in this patient group.
The Company is currently evaluating nomacopan in an ongoing phase 2 trial in patients with bullous pemphigoid.
The BIOCHIP mosaic-based immunofluorescence test is a simple, time- and effort-saving tool that can aid in the diagnosis and screening of bullous diseases.
Investigators sought to determine risk factors associated with the development of bullous pemphigoid.
